Literature DB >> 17417742

Testosterone derivatives are neuroprotective agents in experimental diabetic neuropathy.

I Roglio1, R Bianchi, S Giatti, G Cavaletti, D Caruso, S Scurati, D Crippa, L M Garcia-Segura, F Camozzi, G Lauria, R C Melcangi.   

Abstract

In this study we have assessed the effect of testosterone (T), dihydrotestosterone (DHT) and 5alphaandrostan-3alpha, 17beta-diol (3alpha-diol) therapies on diabetic neuropathy. Diabetes was induced in adult male rats by the injection of streptozotocin and resulted in decreased T and increased 3alpha-diol levels in plasma and in decreased levels of pregnenolone and DHT in the sciatic nerve. Moreover, a reduced expression of the enzyme converting Tinto DHT (i.e., the 5alpha-reductase) also occurs at the level of sciatic nerve, suggesting that the decrease of DHT levels could be due to an impairment of this enzyme. Chronic treatment for 1 month with DHT or 3alpha-diol increased tail nerve conduction velocity and partially counteracted the increase of thermal threshold induced by diabetes. Treatment with DHT increased tibial Na(+),K(+)-ATPase activity and the expression of myelin protein P0 in the sciatic nerve.DHT, 3alpha-diol and T reversed the reduction of intra-epidermal nerve fiber density induced by diabetes. These observations indicate that T metabolites can reverse behavioral, neurophysiological, morphological and biochemical alterations induced by peripheral diabetic neuropathy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17417742     DOI: 10.1007/s00018-007-7002-5

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  15 in total

1.  Nerve-Langerhans cell interactions in diabetes and aging.

Authors:  A L N Doss; P G Smith
Journal:  Histol Histopathol       Date:  2012-12       Impact factor: 2.303

2.  Activation of the liver X receptor increases neuroactive steroid levels and protects from diabetes-induced peripheral neuropathy.

Authors:  Gaia Cermenati; Silvia Giatti; Guido Cavaletti; Roberto Bianchi; Omar Maschi; Marzia Pesaresi; Federico Abbiati; Alessandro Volonterio; Enrique Saez; Donatella Caruso; Roberto Cosimo Melcangi; Nico Mitro
Journal:  J Neurosci       Date:  2010-09-08       Impact factor: 6.167

Review 3.  Sex, diabetes and the kidney.

Authors:  Christine Maric
Journal:  Am J Physiol Renal Physiol       Date:  2009-01-14

Review 4.  Epidermal nerve fiber quantification in the assessment of diabetic neuropathy.

Authors:  Kristina K Beiswenger; Nigel A Calcutt; Andrew P Mizisin
Journal:  Acta Histochem       Date:  2008-04-01       Impact factor: 2.479

5.  Diabetes alters aromatase enzyme levels in sciatic nerve and hippocampus tissues of rats.

Authors:  Nihan Burul-Bozkurt; Can Pekiner; Pelin Kelicen
Journal:  Cell Mol Neurobiol       Date:  2009-10-17       Impact factor: 5.046

6.  Dose-dependent effects of dihydrotestosterone in the streptozotocin-induced diabetic rat kidney.

Authors:  Qin Xu; Anjali Prabhu; Shujing Xu; Michaele B Manigrasso; Christine Maric
Journal:  Am J Physiol Renal Physiol       Date:  2009-06-03

Review 7.  Neuroprotective actions of brain aromatase.

Authors:  Colin J Saldanha; Kelli A Duncan; Bradley J Walters
Journal:  Front Neuroendocrinol       Date:  2009-05-18       Impact factor: 8.606

8.  Expression of aromatase, androgen and estrogen receptors in peripheral target tissues in diabetes.

Authors:  Anjali Prabhu; Qin Xu; Michaele B Manigrasso; Moumita Biswas; Elizabeth Flynn; Radu Iliescu; Edwin D Lephart; Christine Maric
Journal:  Steroids       Date:  2010-01-11       Impact factor: 2.668

9.  Neuroactive Steroid Levels in a transgenic rat model of CMT1A Neuropathy.

Authors:  Donatella Caruso; Samuele Scurati; Ilaria Roglio; Lucilla Nobbio; Angelo Schenone; Roberto C Melcangi
Journal:  J Mol Neurosci       Date:  2008-01-09       Impact factor: 3.444

Review 10.  Neuroactive Steroids and Sex-Dimorphic Nervous Damage Induced by Diabetes Mellitus.

Authors:  Silvia Giatti; Silvia Diviccaro; Roberto Cosimo Melcangi
Journal:  Cell Mol Neurobiol       Date:  2018-08-14       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.